Evaluation of Amnion-derived Multipotent Progenitor (AMP) Cells and Amnion-derived Cellular Cytokine Solution (ST266) in Promoting Craniomaxillofacial Regenerative Bone Healing in Critical Size Calvarial Defects
Abstract
Traumatic injuries often result in critical size bone defects that are unable to heal without treatment. While autologous grafting is the standard of care, it has disadvantages that cell-based and biotherapeutic strategies aim to address. Amnion-derived multipotent progenitor (AMP) cells release ST266, a secretome of biomolecules integral to bone regeneration and angiogenesis. The objective was to determine the regenerative potential of AMP cells and ST266 in healing critical size bone defects in a rat model and use gene analytics to establish a mechanism for pro-osteogenic effects. ST266 enhanced proliferation and migration of MSCs and the proliferation of osteoprogenitor cells in vitro. AMP cells showed slight osteogenic differentiation and good viability on the scaffold. ST266 improved new bone volume and connectivity by 12 weeks, significantly improved angiogenesis at four weeks and bone density at four and 12 weeks with no deleterious effects. ST266 was superior to the AMP cells as the AMP cells appeared to inhibit bone formation. Fluidigm gene analysis showed up-regulation of osteogenic-related genes over time in all groups but no significant differences between groups. Improvement in new bone volume, connectivity and angiogenesis suggests that ST266 is beneficial for bone healing and a higher dose of ST266 may further improve regeneration.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 10, 2017
- Accession Number
- AD1042136
Entities
People
- Alexander J. Burdette
- Banas Richard
- Forest Sheppard
- Jessica M. Stukel
- Michelle E. Thompson
- Teja Guda
Organizations
- Naval Medical Research Unit—San Antonio